Accessibility Menu
Pathfinder Cell Therapy logo

Pathfinder Cell Therapy(OTC) PFND

Current Price$0.00
Market Cap$700.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)-100%
5 Year-100%
1 Year+0%
1 Month+0%
Pathfinder Cell Therapy last closing stock price
MetricPriceDate
Last closeUSD 0.002025-12-29
Pathfinder Cell Therapy stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002025-11-13
1 month+0%USD 0.002025-11-13
3 month+0%USD 0.002025-02-05
Year to date+0%USD 0.002024-12-05
1 year+0%USD 0.002024-12-05
3 year+0%USD 0.002022-12-30
5 year-99.97%USD 0.002020-12-29
Since inception-100%USD 0.062011-09-06

Pathfinder Cell Therapy Financials at a Glance

Market Cap

$700.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$1.39M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-3.11 (Low)

Price

$0.00

Volume

1,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

PFND News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pathfinder Cell Therapy

Pathfinder Cell Therapy, Inc. is an emerging biotechnology firm specializing in regenerative medicine. The company is dedicated to pioneering innovative cell-based treatments aimed at addressing various illnesses, particularly localized cellular injuries within organs.

Products and Services
  • Proprietary cell-based therapies targeting diabetes and kidney disease
  • Innovative treatments for heart attacks and peripheral vascular ailments
  • Research and development in regenerative medicine technologies
Growth Outlook
  • Established in 2008, the company has a solid foundation in biotechnology
  • Focus on addressing significant health issues presents market opportunities
  • Potential for partnerships with healthcare providers and research institutions
Financial Highlights
  • Recent quarterly net income of -$369,000 indicates ongoing investment in R&D
  • Trailing twelve months show a consistent operating loss, reflecting growth strategy
  • Current ratio of 0.012 suggests a need for improved liquidity management
Pathfinder Cell Therapy, Inc. operates in a dynamic sector with a focus on innovative solutions for critical health challenges. The company's commitment to research and development is evident in its financials, which reflect significant investments aimed at advancing its proprietary technologies. Despite recent operating losses, the potential for growth in the regenerative medicine market remains substantial. The company's strategic positioning and ongoing efforts to develop effective treatments could attract interest from investors looking for opportunities in the biotechnology field.
AI Generated • Jul 22, 2026

Industry

Biotechnology

Headquarters

Cambridge, MA 02138, US

PFND Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

31.81%

Return on Capital

N/A

Return on Assets

-1574.53%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$700.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

667.16M

Volume

1.00K

Avg. Volume

0

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$775.00K

EBITDA

-$772.00K

Operating Cash Flow

-$579.00K

Capital Expenditure

$0.00

Free Cash Flow

-$579.00K

Cash & ST Invst.

$4.00K

Total Debt

$5.41M

Pathfinder Cell Therapy Performance Analysis

Pathfinder Cell Therapy sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42014-12-31N/A
Q12015-03-31N/A
Q22015-06-30N/A
Q32015-09-30N/A
Pathfinder Cell Therapy sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42014-12-31-20.0%
Q12015-03-3116.7%
Q22015-06-3020.0%
Q32015-09-30-50.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q3 2015YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$700.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$700.00

N/A

Employees

1

N/A

Net Income

-$369.00K

-3.9%

EBITDA

-$208.00K

+1.9%

Quarterly Fundamentals

Name
Q3 2015YOY CHG

Total Cash

$4.00K

-82.6%

Total Debt

$5.41M

+12.7%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$5.41M

+12.7%

Return on Assets

-15.75%

N/A

Return on Invested Capital

18.83%

N/A

Free Cash Flow

-$178.00K

+21.9%

Operating Cash Flow

-$178.00K

+21.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RGBPRegen BioPharma, Inc.
$0.00+7.14%
BNGIBangi Inc.
$0.00+0.00%
MCETMultiCell Technologies, Inc.
$0.00+0.00%
BPTSYBiophytis S.A.
$0.25+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%
TAT&T
$24.13+0.05%

Questions About PFND

What is the current price of Pathfinder Cell Therapy?

Pathfinder Cell Therapy is trading at $0.00 per share.

What is the 52-week range for Pathfinder Cell Therapy?

Over the past 52 weeks, Pathfinder Cell Therapy has traded between $0.00 and $0.00.

How much debt does Pathfinder Cell Therapy have?

Pathfinder Cell Therapy total debt is unavailable.

How much cash does Pathfinder Cell Therapy have on hand?

Pathfinder Cell Therapy does not have cash on hand data available.

What is Pathfinder Cell Therapy’s dividend yield?

Pathfinder Cell Therapy does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.